Creative Planning’s AbCellera Biologics ABCL Stock Holding History

Creative Planning’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$336K	Sell	42,828 -1,223	-3%	-$5.98K	﹤0.01%	3487
2026 Q1	$154K	Buy	44,051 +2,207	+5%	+$7.94K	﹤0.01%	3807
2025 Q4	$143K	Sell	41,844 -5,889	-12%	-$26.3K	﹤0.01%	3642
2025 Q3	$240K	Buy	47,733 +6,730	+16%	+$29.7K	﹤0.01%	3325
2025 Q2	$141K	Buy	41,003 +2,656	+7%	+$6.61K	﹤0.01%	3352
2025 Q1	$85.5K	Sell	38,347 -33,079	-46%	-$94.9K	﹤0.01%	3275
2024 Q4	$209K	Buy	71,426 +35,627	+100%	+$99.2K	﹤0.01%	2944
2024 Q3	$93.1K	Buy	+35,799	New	+$99.2K	﹤0.01%	3029
2024 Q2	–	Sell	-11,589	Closed	-$52.5K	–	3064
2024 Q1	$52.5K	Sell	11,589 -2,131	-16%	-$10.9K	﹤0.01%	2779
2023 Q4	$78.3K	Buy	+13,720	New	+$63.6K	﹤0.01%	2599
2023 Q3	–	Sell	-11,703	Closed	-$75.6K	–	2904
2023 Q2	$75.6K	Buy	+11,703	New	+$79.9K	﹤0.01%	2393

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Creative Planning's ABCL Position: Q2 2026 in Review

Creative Planning reduced its AbCellera Biologics (ABCL) stake by 2.8% in Q2 2026, selling an estimated $5.98K and leaving 42,828 shares worth $336K. The position accounts for ﹤0.01% of the portfolio, ranked #3487.

Creative Planning first reported a position in ABCL in Q2 2023 and has held it in 11 quarters since. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Creative Planning held 42,828 shares of AbCellera Biologics worth $336K as of Q2 2026.
Creative Planning sold 1,223 AbCellera Biologics shares in Q2 2026, an estimated $5.98K.
AbCellera Biologics made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #3487 holding.
Creative Planning first reported a position in AbCellera Biologics in Q2 2023 and has held it in 11 quarters since.
151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.